VKTX240705C48500
- 2.20
- -1.35-38.03%
Viking Therapeutics Newsroom
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX).And retail traders should know.We noticed this today when the trades showed up on publicly avail
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
BTIG analyst Justin Zelin maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 37.8% and a t
Optimistic Outlook for Viking Therapeutics' Obesity Treatments Amid Upcoming Catalysts and Regulatory Progress
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110
Jefferies analyst Roger Song maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 29.1% and
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 33.85% on an annualized basis producing an average annual return of 46.66%. Currently, Viking Therapeutics has a
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.2% and
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Express News | Viking Therapeutics Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Target Price $105
What Makes Viking Therapeutics, Inc. (VKTX) One of the Best Healthcare Stocks to Buy Under $50?
Morgan Stanley Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $105
Morgan Stanley analyst Michael Ulz initiates coverage on Viking Therapeutics with a Overweight rating and announces Price Target of $105.
Morgan Stanley Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $105
Morgan Stanley analyst Michael Ulz initiates coverage on $Viking Therapeutics(VKTX.US)$ with a buy rating, and sets the target price at $105.According to TipRanks data, the analyst has a success rate
GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca
New York, USA, June 26, 2024 (GLOBE NEWSWIRE) -- GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns
Better Growth Stock: Archer Aviation or Viking Therapeutics?